Integrated Filing — IndAS



General information about company

Scrip Code 530019
NSE Symbol JUBLPHARMA
MSEI Symbol NOTLISTED
ISIN INE700A01033
Name of company JUBILANT PHARMOVA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 29-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 29-Jul-2025   10:45:00
End date and time of board meeting 29-Jul-2025   13:15:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 19007000000
Other income 120000000
Total income 19127000000
2 Expenses
(a) Cost of materials consumed 5205000000
(b) Purchases of stock-in-trade 730000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 247000000
(d) Employee benefit expense 5911000000
(e) Finance costs 490000000
(f) Depreciation, depletion and amortisation expense 981000000
(f) Other Expenses
1 Other Expenses 4018000000 4018000000
Total other expenses 4018000000
Total expenses 17582000000
3 Total profit before exceptional items and tax 1545000000
4 Exceptional items 0
5 Total profit before tax 1545000000
6 Tax expense
7 Current tax 375000000
8 Deferred tax 144000000
9 Total tax expenses 519000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 1026000000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method -1000000
16 Total profit (loss) for period 1025000000
17 Other comprehensive income net of taxes 411000000
18 Total Comprehensive Income for the period 1436000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 1029000000
Total profit or loss, attributable to non-controlling interests -4000000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 1441000000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -5000000
21 Details of equity share capital
Paid-up equity share capital 158000000
Face value of equity share capital 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 6.49
Diluted earnings (loss) per share from continuing operations 6.47
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 6.49
Diluted earnings (loss) per share from continuing and discontinued operations 6.47
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Radiopharma 8686000000 8686000000
2 Allergy Immunotherapy 1914000000 1914000000
3 CDMO- Sterile injectables 3926000000 3926000000
4 CRDMO 3114000000 3114000000
5 Generics 1660000000 1660000000
6 Proprietary Novel Drugs 0 0
7 Unallocable Corporate 128000000 128000000
Total Segment Revenue 19428000000
Less: Inter segment revenue 421000000 421000000
Revenue from operations 19007000000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Radiopharma 986000000 986000000
2 Allergy Immunotherapy 613000000 613000000
3 CDMO- Sterile injectables 431000000 431000000
4 CRDMO 270000000 270000000
5 Generics -4000000 -4000000
6 Proprietary Novel Drugs -62000000 -62000000
7 Unallocable Corporate 0 0
Total Profit before tax 2234000000
i. Finance cost 490000000 490000000
ii. Other Unallocable Expenditure net off Unallocable income 200000000 200000000
Profit before tax 1544000000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Radiopharma 28819000000 28819000000
2 Allergy Immunotherapy 5630000000 5630000000
3 CDMO- Sterile injectables 50095000000 50095000000
4 CRDMO 17238000000 17238000000
5 Generics 12029000000 12029000000
6 Proprietary Novel Drugs 2773000000 2773000000
7 Unallocable Corporate 13449000000 13449000000
Total Segment Asset 130033000000 130033000000
Un-allocable Assets 0 0
Net Segment Asset 130033000000 130033000000
4 Segment Liabilities
Segment Liabilities
1 Radiopharma 9199000000 9199000000
2 Allergy Immunotherapy 784000000 784000000
3 CDMO- Sterile injectables 22987000000 22987000000
4 CRDMO 3821000000 3821000000
5 Generics 2588000000 2588000000
6 Proprietary Novel Drugs 120000000 120000000
7 Unallocable Corporate 26673000000 26673000000
Total Segment Liabilities 66172000000 66172000000
Un-allocable Liabilities 0 0
Net Segment Liabilities 66172000000 66172000000
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -4000000 -4000000
Total Amount of items that will not be reclassified to profit and loss -4000000
2 Income tax relating to items that will not be reclassified to profit or loss -1000000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 414000000 414000000
Total Amount of items that will be reclassified to profit and loss 414000000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 411000000